## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please amend claims 1, 2, 6 and 8 to read as follows.

## **Listing of Claims:**

- 1. (currently amended) An ophthalmological composition, containing, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.
- 2. (currently amended) Either or both of a corneal disorder preventive agent and a corneal disorder treatment agent, having, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.
- 3. (original) Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to Claim 2, with which the corneal disorder is corneal ulcer, corneal epithelial erosion, keratitis, or dry eye.
- 4. (original) Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to Claim 2, wherein the dosage form is an ophthalmic formulation.
- 5. (original) Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to Claim 3, wherein the dosage form is an ophthalmic formulation.
- 6. (currently amended) A corneal epithelium migration promoting agent having, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.
- 7. (original) The corneal epithelium migration promoting agent according to Claim 6, wherein the dosage form is an ophthalmic formulation.

8. (currently amended) Usage of an effective amount of the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug and a corneal disorder treatment method based on such usage.